BI-1607
BI-1607 is a humanized monoclonal antibody targeting FcγRIIB/CD32b. BI-1607 selectively blocks inhibitory FcγRIIB signaling, abrogates its inhibitory function, redirects tumor cell-bound antibodies to activating FcγRs, and its modified Fc region prevents the binding of its own Fc segment to FcγRs. BI-1607 reduces αPD-1 trogocytosis, enhances the effector functions of anti-tumor antibodies (including ADCP and ADCC, promotes intratumoral regulatory T cell (Treg) depletion, myeloid cell reprogramming, induction of interferon-γ (IFN-γ) and CXCL10, and increases the number of activated effector CD8+ T cells. BI-1607 can be used in research related to colorectal cancer, HER2-positive advanced solid tumors, HER2-positive locally advanced or metastatic breast cancer, and HER2-positive metastatic gastric cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Species Reactivity
Human
|
FcγRIIB |
CD32b |
αPD-1 |
IFN-γ |
CXCL10 |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-hCTLA-4 (6-8 week-old, female, 17-20 grams, subcutaneous inoculation of MC38 cells)[1]
-
Dosage:10 mg/kg (in combination with 1 mg/kg ipilimumab)
-
Administration:i.p.; 3 times on days 1, 4, and 8
-
Result:Significantly improved survival compared to ipilimumab alone or BI-1607 alone.
Elevated serum and tumor levels of TNF-α, IFN-γ, and CXCL10 compared to ipilimumab alone.
-
Animal Model:hFcγRIIB ± x mFcγRII-/- C57BL/6[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed no significant depletion of B cells 48 hours after administration, compared with pretreatment levels.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Oldham RJ, et al. Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance. Journal of experimental & clinical cancer research : CR. 2026 Jul 25;45(1):167. [Content Brief]
[2]. Cortés J, et al. A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 Dec 01;31(23):4953-4963. [Content Brief]
[5]. Yasuda T, et al. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024 Jul;10(7):627-642. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
BI-1607 関連分類
HY-P991582 関連分類
Powered by Bioz
Keywords
- BI-1607
- BI1607
- BI 1607
- Fc Receptor (FcR)
- IFNAR
- PD-1/PD-L1
- CXCR
- colon adenocarcinoma
- ADCP
- ADCC
- colorectal cancer
- HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma
- gastric cancer
- HER2-positive advanced solid tumors
- FcγRIIB
- HER2-positive locally advanced or metastatic breast cancer
- CD32b
- Inhibitor
- inhibitor
- inhibit